Atherosclerosis The Road Ahead

Serum cholesterol is carried by several lipoprotein parti-Medicine and Atherosclerosis cles that perform the complex physiologic tasks of * Department of Medicine transporting dietary and endogenously produced lipids Division of Endocrinology and Metabolism (reviewed in Witztum and Steinberg, 1995). Chylomicrons † Department of Cellular and Molecular Medicine provide the primary means of transport of dietary lipids, while very low density lipoproteins (VLDL), low density 9500 Gilman Drive lipoproteins (LDL), and high density lipoproteins (HDL) La Jolla, California 92093 function to transport endogenous lipids. Triglyceride-rich VLDL particles containing apolipoprotein B-100 (apo B-100) and apolipoprotein E (apo E) are synthesized by the liver and function to transport fatty acids to adi-Complications of atherosclerosis are the most common pose tissue and muscle. After triglyceride removal in causes of death in Western societies. In broad outline, peripheral tissues, a portion of the remaining VLDL rem-atherosclerosis can be considered to be a form of nants are metabolized to LDL particles by further re-chronic inflammation resulting from interaction between moval of core triglycerides and dissociation of apolipo-modified lipoproteins, monocyte-derived macrophages, proteins other than apo B-100. In humans, the majority T cells, and the normal cellular elements of the arterial of serum cholesterol is carried by LDL particles. wall. This inflammatory process can ultimately lead to While LDL has an essential physiological role as a the development of complex lesions, or plaques, that vehicle for the delivery of cholesterol to peripheral tis-protrude into the arterial lumen. Plaque rupture and sues, increased LDL cholesterol levels are associated thrombosis results in the acute clinical complications of with increased risk of cardiovascular disease. LDL is myocardial infarction and stroke (Navab et al., 1996; taken up by cells via LDL receptors that recognize an Ross, 1999; Steinberg and Witztum, 1999). Among the N-terminal domain of apo B-100. The circulating level many genetic and environmental risk factors that have of LDL is determined in large part by its rate of uptake been identified by epidemiologic studies (Table 1), elevated levels of serum cholesterol are probably unique through the hepatic LDL receptor pathway, as evi-in being sufficient to drive the development of athero-denced by the fact that lack of functional LDL receptors sclerosis in humans and experimental animals, even in is responsible for the massive accumulation of LDL in the absence of other known risk factors. The elucidation patients with homozygous familial hypercholesterol-of molecular mechanisms that control cholesterol bio-emia (Goldstein and Brown, 1977). …

[1]  Jean-Marc A. Lobaccaro,et al.  Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ , 2000 .

[2]  M. Cybulsky,et al.  Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. , 1991, Science.

[3]  Lee Goldman,et al.  Cecil Textbook of Medicine , 1985 .

[4]  I. Björkhem,et al.  Mechanism of degradation of the steroid side chain in the formation of bile acids. , 1992, Journal of lipid research.

[5]  M. Daemen,et al.  Requirement for CD154 in the progression of atherosclerosis , 1999, Nature Medicine.

[6]  D. Rader,et al.  Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Gotto,et al.  The hyperlipoproteinemias. , 1989, The Medical clinics of North America.

[8]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[9]  N. Risch.  Searching for genetic determinants in the new millennium , 2000, Nature.

[10]  P. Denéfle,et al.  Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. , 1999, Circulation.

[11]  O. Quehenberger,et al.  Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. , 1999, Journal of lipid research.

[12]  P. Thorén,et al.  Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Rader,et al.  Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. , 1999, Circulation.

[14]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[15]  M. Brown,et al.  A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Arnaud Cd,et al.  Selective estrogen receptor modulators and postmenopausal health. , 2000 .

[17]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[18]  M. Brown,et al.  The low-density lipoprotein pathway and its relation to atherosclerosis. , 1977, Annual review of biochemistry.

[19]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[20]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[21]  R. D. Dyer,et al.  Attenuation of diet‐induced atherosclerosis in rabbits with a highly selective 15‐lipoxygenase inhibitor lacking significant antioxidant properties , 1997, British journal of pharmacology.

[22]  D. Rader,et al.  Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. , 1999, The Journal of clinical investigation.

[23]  C. Sensen,et al.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.

[24]  Roland Somogyi,et al.  Large Scale Gene Expression Analysis of Cholesterol-loaded Macrophages* , 2000, The Journal of Biological Chemistry.

[25]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[26]  H. Jamil,et al.  An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. , 1998, Science.

[27]  S. Perrey,et al.  Absence of ACAT-1 Attenuates Atherosclerosis but Causes Dry Eye and Cutaneous Xanthomatosis in Mice with Congenital Hyperlipidemia* , 2000, The Journal of Biological Chemistry.

[28]  J L Witztum,et al.  Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. , 1997, The Journal of clinical investigation.

[29]  S. Yusuf,et al.  The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data , 1995, Annals of Internal Medicine.

[30]  D. Behr-Roussel,et al.  Effect of Chronic Treatment With the Inducible Nitric Oxide Synthase Inhibitor N-Iminoethyl-l-Lysine or With l-Arginine on Progression of Coronary and Aortic Atherosclerosis in Hypercholesterolemic Rabbits , 2000, Circulation.

[31]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[32]  R. Evans,et al.  A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis , 2001 .

[33]  K. Wakitani,et al.  A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.

[34]  A. Vaughan,et al.  The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.

[35]  T. Langmann,et al.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.

[36]  G. Struhl,et al.  Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb , 1998, Nature.

[37]  H. Hobbs,et al.  The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. , 1990, Annual review of genetics.

[38]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[39]  G. Silverman,et al.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. , 2000, The Journal of clinical investigation.

[40]  S. Heath,et al.  Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[41]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[42]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[43]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[44]  A. Beaudet,et al.  P-Selectin or Intercellular Adhesion Molecule (Icam)-1 Deficiency Substantially Protects against Atherosclerosis in Apolipoprotein E–Deficient Mice , 2000, The Journal of experimental medicine.

[45]  T. Arai,et al.  Increased LDL cholesterol and atherosclerosis in LDL receptor-deficient mice with attenuated expression of scavenger receptor B1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[46]  P. Libby,et al.  Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. , 1997, The American journal of pathology.

[47]  J. D. Smith,et al.  Mouse models of atherosclerosis. , 1998, Laboratory animal science.

[48]  E. Nabel,et al.  Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  A. Tall,et al.  1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[50]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit. A new look at old data. , 1995, Circulation.

[51]  N. Santanello,et al.  Cholesterol reduction yields clinical benefit: impact of statin trials. , 1998, Circulation.

[52]  T. Kodama,et al.  Scavenger receptor family proteins: roles for atherosclerosis, host defence and disorders of the central nervous system , 1998, Cellular and Molecular Life Sciences CMLS.

[53]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[54]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[55]  J. Heinecke.  Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. , 1998, Atherosclerosis.

[56]  M. Bureau,et al.  Protective role of interleukin-10 in atherosclerosis. , 1999, Circulation research.

[57]  E. Winzeler,et al.  Genomics, gene expression and DNA arrays , 2000, Nature.

[58]  N. Maeda,et al.  Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Chisolm,et al.  Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 beta-hydroperoxycholesterol. , 1996, Journal of lipid research.

[60]  G. Hansson,et al.  Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[61]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[62]  S. Fazio,et al.  Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation , 1995, Science.

[63]  P. Libby,et al.  CD40 signaling in vascular cells: a key role in atherosclerosis? , 1998, Atherosclerosis.

[64]  A. Tall,et al.  IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. , 1997, The Journal of clinical investigation.

[65]  Yukiko Kurihara,et al.  A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection , 1997, Nature.

[66]  R. Hynes,et al.  The combined role of P- and E-selectins in atherosclerosis. , 1998, The Journal of clinical investigation.

[67]  T. Collins,et al.  The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. , 1998, Current opinion in lipidology.

[68]  R. Terkeltaub,et al.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.

[69]  I. Sviták.  Comparisons , 1981, Telos.

[70]  M. Bennett.  Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. , 1999, Cardiovascular research.

[71]  B. Spiegelman.  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[72]  Michael Ginsberg,et al.  Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[73]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[74]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[75]  J. George,et al.  Overexpression of 15-Lipoxygenase in Vascular Endothelium Accelerates Early Atherosclerosis in LDL Receptor–Deficient Mice , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[76]  J. Piette,et al.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.

[77]  P. Carmeliet.  Proteinases in cardiovascular aneurysms and rupture: targets for therapy? , 2000, The Journal of clinical investigation.

[78]  K. Williams,et al.  The response-to-retention hypothesis of atherogenesis reinforced. , 1998, Current opinion in lipidology.

[79]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[80]  A. Lusis,et al.  Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. , 1999, Circulation research.

[81]  D. Grainger,et al.  Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. , 1997, Circulation.

[82]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[83]  T. Carew,et al.  Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. , 1989, Arteriosclerosis.

[84]  E. Rubin,et al.  ApoA-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apoB transgenic mice. , 1998, Journal of lipid research.

[85]  W. Miller,et al.  Identification of a coordinate regulator of interleukins 4, 13, and 5 by cross-species sequence comparisons. , 2000, Science.

[86]  A. Chait,et al.  Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[87]  R. Young,et al.  Biomedical Discovery with DNA Arrays , 2000, Cell.

[88]  C. Hennekens.  Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. , 1998, Circulation.

[89]  D. Rader,et al.  Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice , 2000, The Journal of Immunology.

[90]  T. Carew,et al.  Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. , 1989, Arteriosclerosis.

[91]  P. Libby,et al.  The unstable atheroma. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[92]  G. Hansson.  Cell-mediated immunity in atherosclerosis , 1997, Current opinion in lipidology.

[93]  S. Yusuf,et al.  Vitamin E supplementation and cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[94]  M. Territo,et al.  Interleukin-10 blocks atherosclerotic events in vitro and in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[95]  B. Rollins,et al.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.

[96]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[97]  J. D. Smith,et al.  T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[98]  A. Tall,et al.  Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[99]  B. Staels,et al.  Peroxisome proliterator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis , 1999 .

[100]  D. Witte,et al.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice. , 1998, The Journal of clinical investigation.

[101]  Robert V Farese,et al.  Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. , 2000, The Journal of clinical investigation.

[102]  J. Knowles,et al.  Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. , 2000, The Journal of clinical investigation.

[103]  J. Auwerx,et al.  Regulation of apo A-I gene expression by fibrates. , 1997, Atherosclerosis.

[104]  M. Davies,et al.  Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.

[105]  J. Kluger.  Beyond cholesterol. , 1997, Time.

[106]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[107]  G. Silverman,et al.  Immunological responses to oxidized LDL. , 2000, Free radical biology & medicine.

[108]  A. Tall,et al.  IFN- g Potentiates Atherosclerosis in ApoE Knock-out Mice , 1997 .

[109]  D. Shih,et al.  Combined Serum Paraoxonase Knockout/Apolipoprotein E Knockout Mice Exhibit Increased Lipoprotein Oxidation and Atherosclerosis* , 2000, The Journal of Biological Chemistry.

[110]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .